Llwytho...
Predicting Corticosteroid Free Endoscopic Remission with Vedolizumab in Ulcerative Colitis
BACKGROUND: Vedolizumab is an effective therapy for ulcerative colitis (UC), but costly and slow to work. New clinical responses occur after 30 weeks of therapy. AIMS: We aimed to enable physicians, patients, and insurers to predict whether a patient with UC will respond to vedolizumab at an early t...
Wedi'i Gadw mewn:
| Cyhoeddwyd yn: | Aliment Pharmacol Ther |
|---|---|
| Prif Awduron: | , , , , , , |
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
2018
|
| Pynciau: | |
| Mynediad Ar-lein: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5814341/ https://ncbi.nlm.nih.gov/pubmed/29359519 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/apt.14510 |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|